Page 372 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C2.1. Eligibility criteria, follow-up protocols, triggers for intervention and definition of progression in cohorts of active
surveillance/ watchful waiting/other observational management strategies (continued)

Center, Country Eligibility criteria Followup or monitoring protocol Triggers for intervention/ Definition of
[PMID] active therapy progression
Enrollment year
PRIAS, Originating from PSA at 3 mo, DRE at 6 mo and standard rebiopsy after 1 yr. PSA DT 0 to 3 yr, T state >2 NR
Netherlands 120 the ERSPC. 151 or rebiopsy findings exceed
[19817747] Histologically study inclusion thresholds
proven
2006 – ongoing adenocarcinom
a of the
prostate; fit for
curative
treatment; PSA-
level at
diagnosis ≤ 10
ng/mL; PSA
density ≤ 0.2
ng/ml/ml;
clinical stage
T1c or T2;
adequate
biopsy sampling
according to
biopsy protocol;
Gleason score
≤3+3=6;
maximal 2
biopsy cores
invaded with
prostate cancer;
willing to attend
the follow-up
visits.

C-104